Malignant solitary fibrous tumor of urinary bladder: A rare clinical entity

Kratiras, Z.; Spapis, Vasileios; Koniaris, Efthymios; Kozyrakis, Diomidis; Skriapas, Konstantinos

doi:10.4081/aiua.2019.2.135

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age at presentation varies between fourth and sixth decades of life with slightly high predominance in men. Approximately 18 cases have been reported occurring in the bladder with only 2 cases among females [2 , 3] . The first 5 cases of SFTs in mediastinum and pleura were reported in 1931 by Klemperer.…”

Section: Discussionmentioning

confidence: 99%

Solitary fibrous tumor of the urinary bladder: An unusual case report with literature review

Vargas

Gandhi

Bajaj

et al. 2021

Radiology Case Reports

View full text Add to dashboard Cite

Solitary fibrous tumor is neoplasm of mesenchymal origin commonly involving visceral pleura however we are presenting an unusual case with involvement of urinary bladder. It is generally indolent in nature therefore proper diagnosis is required for complete characterization to avoid unnecessary extensive surgical resection. Our patient was a 64-year-old female who presented with lower abdominal fullness with change in her bowel movement pattern. On imaging partially necrotic mass with heterogenous enhancement was found which was later biopsied and resected with clean surgical margin. Solitary fibrous tumor is overall a benign tumor with satisfactory outcome. Physicians should keep it in a differential of pelvic masses and with the risk recurrence, 6 monthly follow up imaging are usually required after resection.

show abstract

Section: Discussionmentioning

confidence: 99%

Solitary fibrous tumor of the urinary bladder: An unusual case report with literature review

Vargas

Gandhi

Bajaj

et al. 2021

Radiology Case Reports

View full text Add to dashboard Cite

show abstract

“…A few studies showed that pelvic [27,30,41], abdominal [27,42], and pleural [27,40,43] SFTs tend to be larger than tumors appearing in other locations, and extrapleural SFTs may show potentially malignant behavior [44], especially those with limb localization [45]. Generally, over the years, SFTs have been described in various localizations, including the liver [46,47], kidney [48][49][50], pancreas [23,51,52], sigmoid colon [31], mesocolon [14], omentum [53,54], urinary bladder [55], caecum wall [56], mesorectum [41], prostate [57], spermatic cord [58], testis [59], scrotum [60], female gynecological tract, especially the vulva [61,62], vagina [63], breast [64][65][66], heart and pericardium [33,67,68], epicardium [69], pulmonary artery [70], trachea [71], larynx [32,72], tongue [15], salivary glands [73]<...…”

Section: Anatomical Locationmentioning

confidence: 99%

“…Interestingly, FNA (fine needle aspiration), together with nuclear STAT6 immunoreactivity, has been reported to be an additional tool in the diagnosis of SFTs [117]. However, a core needle biopsy or an open incisional biopsy [118] and an immunohistochemical analysis are needed to confirm the diagnosis [55]. In STS, an open incisional biopsy may comprise treatment due to tumor dissemination, and as such could only be indicated in singular cases, e.g., in unfeasibility of a core needle biopsy [119].…”

Section: Diagnosismentioning

confidence: 99%

Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors

Janik,

Terlecka,

Spałek

et al. 2023

Cancers

View full text Add to dashboard Cite

Solitary fibrous tumors (SFT) are rare mesenchymal neoplasms that account for less than 2% of all soft tissue masses. In the latest WHO 2020 Classification of Soft Tissue Tumors, extrameningeal SFT was listed as intermediate (rarely metastasizing) or malignant neoplasms. Due to the lack of characteristic clinical features, their diagnosis and treatment remain challenging. The pathogenesis of SFT is often associated with the presence of fusions of the NAB2-STAT6 gene on the 12q13 chromosome. Cytoplasmic CD34 positive staining is considerably characteristic for most SFTs; less frequently, factor XII, vimentin, bcl-2, and CD99 are present. A key factor in the diagnosis is the prevalent nuclear location of STAT6 expression. Radical resection is the mainstay of localized SFTs. In the case of unresectable disease, only radiotherapy or radio-chemotherapy may significantly ensure long-term local control of primary and metastatic lesions. To date, no practical guidelines have been published for the treatment of advanced or metastatic disease. Classical anthracycline-based chemotherapy is applicable. The latest studies suggest that antiangiogenic therapies should be considered after first-line treatment. Other drugs, such as imatinib, figitumumab, axitinib, and eribulin, are also being tested. Definitive radiotherapy appears to be a promising therapeutic modality. Since standards for the treatment of advanced and metastatic diseases are not available, further investigation of novel agents is necessary.

show abstract

“…Taken together, as mediators of endocytosis and related to cell signaling, caveolins are implicated in both carcinogenesis and tumoral suppression [ 189 ], and they probably act as promoters in the case of malignant bladder tumors [ 62 , 190 ]. However, and despite the potential interest that proteins found in the serosa may have, the tumoral lesions arising in this bladder layer are exceedingly rare [ 191 , 192 ]; thus, the influence of this molecular environment in BC is largely unknown [ 193 , 194 , 195 ].…”

Section: Insights Into the Histopathology Of Bladder Cancer By Proteomicsmentioning

confidence: 99%

Proteomics as a Complementary Technique to Characterize Bladder Cancer

López-Cortés

Vázquez‐Estévez

Fernandez

et al. 2021

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is the most common tumor of the urinary tract and is conventionally classified as either non-muscle invasive or muscle invasive. In addition, histological variants exist, as organized by the WHO-2016 classification. However, innovations in next-generation sequencing have led to molecular classifications of BC. These innovations have also allowed for the tracing of major tumorigenic pathways and, therefore, are positioned as strong supporters of precision medicine. In parallel, immunohistochemistry is still the clinical reference to discriminate histological layers and to stage BC. Key contributions have been made to enlarge the panel of protein immunomarkers. Moreover, the analysis of proteins in liquid biopsy has also provided potential markers. Notwithstanding, their clinical adoption is still low, with very few approved tests. In this context, mass spectrometry-based proteomics has remained a step behind; hence, we aimed to develop them in the community. Herein, the authors introduce the epidemiology and the conventional classifications to review the molecular classification of BC, highlighting the contributions of proteomics. Then, the advances in mass spectrometry techniques focusing on maintaining the integrity of the biological structures are presented, a milestone for the emergence of histoproteomics. Within this field, the review then discusses selected proteins for the comprehension of the pathophysiological mechanisms of BC. Finally, because there is still insufficient knowledge, this review considers proteomics as an important source for the development of BC therapies.

show abstract

Malignant solitary fibrous tumor of urinary bladder: A rare clinical entity

Cited by 6 publications

References 0 publications

Solitary fibrous tumor of the urinary bladder: An unusual case report with literature review

Solitary fibrous tumor of the urinary bladder: An unusual case report with literature review

Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors

Proteomics as a Complementary Technique to Characterize Bladder Cancer

Contact Info

Product

Resources

About